CN100384466C - Chinese proprietary medicine for regulating blood pressure and application thereof - Google Patents
Chinese proprietary medicine for regulating blood pressure and application thereof Download PDFInfo
- Publication number
- CN100384466C CN100384466C CNB200610017825XA CN200610017825A CN100384466C CN 100384466 C CN100384466 C CN 100384466C CN B200610017825X A CNB200610017825X A CN B200610017825XA CN 200610017825 A CN200610017825 A CN 200610017825A CN 100384466 C CN100384466 C CN 100384466C
- Authority
- CN
- China
- Prior art keywords
- medicine
- chinese patent
- blood pressure
- weight portion
- patent medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a Chinese patent medicine for regulating blood pressure, which is prepared from constituents A: alcohol extractives of ginseng and notoginseng having the weight ratio of 2:1, constituents B: alcohol extractives of hemlock parsley and curcuma root having the weight ratio of 1:1, constituents C: fine powder of leech and red ochre having the weight ratio of 1:1. The three constituents A, B and C having the weight ratio of 2:1:1 are uniformly mixed to prepare the Chinese patent medicine. The medicine with the compound as the main active constituents can be prepared into oral administration medicines of tablets, capsules, granules, etc. The compound is used for preparing medicine for treating hypertension and has good treatment effect.
Description
Technical field
The present invention relates to a kind of Chinese medicine and application thereof, relate in particular to a kind of Chinese patent medicine and application thereof of blood pressure regulation.
Background technology
Hypertension (Hypertension) is modal cardiovascular disease, prevalence height not only, and can cause the serious heart, brain, kidney complication, be the main hazard factor of apoplexy, coronary heart disease.Along with acute infectious disease is controlled, the prolongation of crowd's life expectancy, the serious harm of non-infective diseases such as cardiovascular disease more and more comes into one's own.In recent years, the western medicine hypertension obtains considerable progress, general diuretic, beta-blocker, calcium antagonist, the angiotensin ii receptor antagonist etc. of adopting of Western medicine more, patient's blood pressure has reduced, but clinical symptoms is obviously alleviated, and complication is more, and need take medicine all the life.And traditional traditional Chinese medical science is having great advantage aspect the hypertension in treatment, emphasizes that dialectical opinion controls, regulating yin and yang, and the too many levels conditioning has characteristics such as inexpensive, that toxic and side effects is little, attempts to seek from the Chinese medicine aspect its treatment approach in the native land.But the Chinese patent medicine that lacks at present effective blood pressure regulation clinically with the active extract composition of Radix Notoginseng, Radix Curcumae, Rhizoma Chuanxiong, Hirudo, the Haematitum Chinese patent medicine as blood pressure regulation, yet there are no relevant report.
Summary of the invention
The Chinese patent medicine of the new blood pressure regulation that the object of the present invention is to provide that a kind of prescription is simplified, determined curative effect, side effect is little overcomes existing Western medicine deficiency; Another purpose of the present invention is to provide the application of this composition of medicine.
For realizing the object of the invention, technical scheme is as follows:
Headache and dizzy, the person's back that the present invention shows in clinical pathological process according to hypertension is strong, feeling of oppression and pain in the chest, numb limbs and tense tendons even apoplectic hemiplegia, body of the tongue are dim red or purple dim, it is summed up as " syndrome of blood stasis ", and non-traditional hyperactivity of YANG due to deficiency of YIN or hepatic and renal YIN deficiency institute can be general it.Therefore stagnation of blood stasis can be used as a double disease and also can be used as independent disease type and be present in the hypertension, so the present invention is aided with blood circulation promoting and blood stasis dispelling as therapeutic scheme with disease, on the basis of traditional Chinese medicine theory, utilization modern medicine theory is selected the Chinese Traditional Medicines of Radix Notoginseng, Radix Curcumae, Rhizoma Chuanxiong, Hirudo, the composite composition blood pressure regulation of Haematitum for use, be activating blood and removing stasis Method specifically utilization in the treatment hypertension, better therapeutic effect arranged improving the hypertension microcirculation disturbance.
This medicine forms by following component is composite, and each component is in weight portion:
A component: with the alcohol extract of 2: 1 blended Radix Ginsengs of weight portion, Radix Notoginseng crude drug;
B component: with the alcohol extract of 1: 1 blended Rhizoma Chuanxiong of weight portion, Radix Curcumae crude drug;
C component: with the fine powder of 1: 1 blended Hirudo of weight portion, Haematitum crude drug; A, B, C three components are made Chinese patent medicine with 2: 1: 1 weight portion mix homogeneously.With the said composition is that its dosage form of main active can be made into oral formulations such as tablet, capsule, granule.Said composition is applied to preparation treatment hypertension drug, better therapeutic effect is arranged.
Beneficial effect of the present invention is that this Chinese patent medicine is according to hypertension: one of excessive rising of liver-YANG, obstruction of collaterals by blood stasis pathogenesis, with suppressing the hyperactive liver and subsiding YANG, blood circulation promoting and blood stasis dispelling as treatment means, through demonstration testing repeatedly, develop by Radix Ginseng, Radix Notoginseng, Radix Curcumae, Rhizoma Chuanxiong, Hirudo, Haematitum is the hypertensive pure Chinese medicinal preparation of treatment of main component, have invigorate blood circulation, antihypertensive effect, prescription letter refining, reasonable recipe, taking convenience, evident in efficacy, being clinical experience side for many years, is control, treatment hypertension excessive rising of liver-YANG, obstruction of collaterals by blood stasis effective experience side; And the pathogenesis that links closely, treating both the principal and secondary aspects of a disease, the flavour of a drug refine has very important function to improving the hypertension microcirculation disturbance.
The specific embodiment
For the present invention is better illustrated, as follows for embodiment:
One Radix Ginseng, Radix Notoginseng extract preparation:
Radix Ginseng decoction pieces 600g and pseudo-ginseng coarse powder 300g mix, and add 80% ethanol of 8 times of medical material weight, and reflux, extract, 3 times was extracted respectively 2,2,1 hours, filter, merge extractive liquid, reclaims ethanol to there not being alcohol, and be condensed into the aqueous solution of 1g crude drug/ml, and respectively extracting 3 times through ethyl acetate, water-saturated n-butanol, the reclaim under reduced pressure n-butyl alcohol is done near, add the small amount of methanol dissolving, in methanol solution, add ethyl acetate again, separate out precipitation, filter, get precipitation, drying, pulverize, cross 55 mesh sieves, promptly.
The preparation of two Rhizoma Chuanxiongs, Radix Curcumae extract:
Get Rhizoma Chuanxiong, Radix Curcumae 500 gram coarse powder mix, add 70% ethanol of 8 times of medical material weight, reflux, extract, 2 times was extracted respectively 2 hours, 1.5 hours, filter, merge extractive liquid, reclaims ethanol to there not being alcohol, concentrated solution through macroporous adsorbent resin with 30% ethanol elution, collect eluent, concentrating under reduced pressure, drying, pulverizing are promptly.
Three Hirudos, Haematitum preparation: Hirudo, each 500 gram proportioning of Haematitum are ground into fine powder and cross 200 orders.
Four solid preparations preparation: with Radix Ginseng, Radix Notoginseng extract: Rhizoma Chuanxiong, Radix Curcumae extract: Hirudo Haematitum fine powder is aided with pharmaceutic adjuvant and makes tablet or capsule by 2: 1: 1 proportioning mix homogeneously.Every (sheet) weighs 0.30 gram, contains Chinese medicine extract 0.15 gram.
Usage and dosage: oral, each 8-10 grain (sheet), every day 2 times.
The clinical verification of the blood pressure regulation capsule Chinese patent medicine that makes with the present invention is that example further specifies the present invention.
1, physical data
Diagnostic criteria reaches standard by stages
Hyperpietic diagnostic criteria and grade scale be all with reference to the diagnostic criteria of WHO in 1999 about hypertension, the liver-Yang sthenia type in the dizzy clinical research guideline of tcm diagnosis standard reference new Chinese medicine treatment.
The case source: 86 routine patients are divided into test group and matched group at random.Test group 46 examples, wherein male 22 examples, women 24 examples, 50.54 ± 5.45 years old mean age, average course of disease 12.85 ± 5.40 years; Matched group 40 examples, wherein male 21 examples, women 19 examples, 55.80 ± 10.50 years old mean age, average course of disease 11.20 ± 7.20 years.Two groups before sex, age, the course of disease, treatment pressure value, tcm symptom relatively etc. all do not have significant difference (P＜0.05) in the aspect.
2, Therapeutic Method
The blood pressure decreasing capsule of invigorating blood circulation that test group makes with the present invention, each 8, every day 2 times.Matched group NAOLIQING WAN (production of Shandong Dong A A Jiao Group LinQing HuaWei medicine Co., Ltd), each 10 balls, every day 2 times.Two groups is a course of treatment with 4 weeks all, a course of treatment
After the end, the statistics curative effect.
3, observation item
Observe 10 symptoms performances such as the dim red or dim purple of blood pressure level and dizzy, headache dizziness and distending sensation of the head before and after two groups of treatments, neck stiffback, flushing conjunctival congestion, numb limbs and tense tendons, nervous, feeling of oppression and pain in the chest, being irritable and getting angry easily, insomnia, tinnitus, body of the tongue.
4, efficacy assessment standard
The efficacy of antihypertensive treatment evaluation criteria is formulated standard with reference to national cardiovascular epidemiology in 1979 and crowd prevention and treatment forum.Tcm symptom total effects evaluation criteria is evaluated with reference to Ministry of Public Health promulgation new Chinese medicine clinical research guideline in 1993.
5, statistical procedures
Adopt Ridit analysis and t check that related data is carried out statistical procedures
6, Clinical results
6.1 two groups of efficacy of antihypertensive treatment and blood pressure lowering amplitude are relatively
Two groups of efficacy of antihypertensive treatment relatively
Analyze through Ridit, P＜0.05, test group is better than matched group.
As seen from table, test group 46 routine produce effects 12 examples, effective 27 examples, total effective rate 84.8% is better than matched group.Two groups of efficacy of antihypertensive treatment comparisons are analyzed through Ridit significant difference P＜0.05.
Two groups of blood pressure lowering amplitudes relatively
* before expression and the treatment relatively P＜0.01 △ represent with matched group relatively P＜0.01 as seen from table, before and after the treatment systolic pressure diastolic pressure respectively with self more equal utmost point significant difference P＜0.01.
6.2 tcm symptom curative effect
The tcm symptom curative effect relatively
Analyze through Ridit, P＜0.05, test group is better than matched group.
As seen from table, test group 46 routine total effective rates 97.8% are better than matched group.Two groups of efficacy of antihypertensive treatment comparisons are analyzed through Ridit significant difference P＜0.05.
Claims (3)
1. the Chinese patent medicine of a blood pressure regulation, it is characterized in that: this medicine forms by following component is composite, and each component is in weight portion:
A component: with the alcohol extract of 2: 1 blended Radix Ginsengs of weight portion, Radix Notoginseng crude drug;
B component: with the alcohol extract of 1: 1 blended Rhizoma Chuanxiong of weight portion, Radix Curcumae crude drug;
C component: with the fine powder of 1: 1 blended Hirudo of weight portion, Haematitum crude drug;
A, B, C three components are made Chinese patent medicine with 2: 1: 1 weight portion mix homogeneously.
2. the Chinese patent medicine of blood pressure regulation as claimed in claim 1, it is characterized in that: making with the said composition is tablet or the capsule or the particulate oral preparation of main active.
3. the application of Chinese patent medicine as claimed in claim 1 or 2 in preparation treatment hypertension drug is characterized in that: said composition is used for preparation treatment hypertension drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200610017825XA CN100384466C (en) | 2006-05-24 | 2006-05-24 | Chinese proprietary medicine for regulating blood pressure and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200610017825XA CN100384466C (en) | 2006-05-24 | 2006-05-24 | Chinese proprietary medicine for regulating blood pressure and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1883688A CN1883688A (en) | 2006-12-27 |
| CN100384466C true CN100384466C (en) | 2008-04-30 |
Family
ID=37582072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB200610017825XA Expired - Fee Related CN100384466C (en) | 2006-05-24 | 2006-05-24 | Chinese proprietary medicine for regulating blood pressure and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100384466C (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1113781A (en) * | 1994-06-16 | 1995-12-27 | 傅正和 | Viscosity-reducing and antithrombotic tablet and its producing technology |
| CN1223122A (en) * | 1998-01-13 | 1999-07-21 | 彭文瑞 | Medicine for curing cerebrovascular and cardiovascular diseases and preparation process thereof |
-
2006
- 2006-05-24 CN CNB200610017825XA patent/CN100384466C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1113781A (en) * | 1994-06-16 | 1995-12-27 | 傅正和 | Viscosity-reducing and antithrombotic tablet and its producing technology |
| CN1223122A (en) * | 1998-01-13 | 1999-07-21 | 彭文瑞 | Medicine for curing cerebrovascular and cardiovascular diseases and preparation process thereof |
Non-Patent Citations (2)
| Title |
|---|
| 自拟脑通灵汤治疗急性脑梗塞87例. 程冬云.内蒙古中医药，第20卷第2期. 2001 |
| 自拟脑通灵汤治疗急性脑梗塞87例. 程冬云.内蒙古中医药，第20卷第2期. 2001 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1883688A (en) | 2006-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100366280C (en) | Medicinal composition for treating hypertension, its preparation method and use | |
| CN102861242B (en) | Chinese medicine composition for preventing and treating dizziness and preparation method thereof | |
| CN101897821B (en) | Granular preparation for promoting blood circulation, dredging collaterals and relieving pain and preparation method as well as detection method thereof | |
| CN101095768B (en) | Chinese traditional medicine capsule for treating primary hypertension for persons in middle and old age | |
| CN103285343B (en) | Medicine for treating liver cancer and preparation method thereof | |
| CN102961584A (en) | Traditional Chinese medicine composition capable of relieving fatigue, as well as preparation method and application thereof | |
| CN102488838A (en) | Traditional Chinese medicine composition used for treating viral myocarditis | |
| CN105326939A (en) | Traditional Chinese medicine for treating heart and cerebral vusculer diseases | |
| CN104623314A (en) | Medicine composition for treating dry mouth and bitter taste and preparation method thereof | |
| CN100384466C (en) | Chinese proprietary medicine for regulating blood pressure and application thereof | |
| CN103110100A (en) | Korean medical healthcare food composition as well as preparation method and application thereof | |
| CN103386006B (en) | A kind of application of Chinese medicine composition in the dull-witted drug for the treatment of is prepared | |
| CN105727089A (en) | Application of medicine composition containing folium artemisiae argyi to preparing medicine for treating irritable bowel syndrome | |
| CN105194355A (en) | Traditional Chinese medicine preparation for treating primary hypertension | |
| CN1857531A (en) | Recipe, preparing process and application of Chinese medicine preparation for treating diabetic retinopathy | |
| CN100430072C (en) | Chinese-medicinal preparation for treating cardiovascular and cerebrovascular diseases | |
| CN100486621C (en) | Chinese medicinal composition for treating hemilateral headache and its preparation method | |
| CN104352672A (en) | Tortoise plastron-containing traditional Chinese medicine composition for treating diabetes | |
| CN103263581A (en) | Shuangshen capsule for reducing blood sugar | |
| CN110841007B (en) | Traditional Chinese medicine composition for treating cerebral apoplexy sequela and application thereof | |
| CN105477384A (en) | Traditional Chinese medicine composition capable of reducing blood pressure and preparation method of composition | |
| CN105477373A (en) | Chinese patent medicine for treating myocardial infarction and preparation method thereof | |
| CN104435149A (en) | Traditional Chinese medicine composition containing kadsura pepper stem for treating gout | |
| CN104547742A (en) | Traditional Chinese medicine preparation for treating hypertension and preparation method thereof | |
| CN101647911B (en) | Traditional Chinese medicine composite and preparation for treating headache and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Zhang Xianchen Document name: Notice of application for publication of patent for invention and entry into the substantive examination procedure |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080430 |